Orion Portfolio Solutions LLC lowered its position in IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 12.5% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 6,360 shares of the medical research company’s stock after selling 910 shares during the period. Orion Portfolio Solutions LLC’s holdings in IQVIA were worth $1,380,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Riverview Trust Co purchased a new stake in IQVIA in the first quarter worth approximately $25,000. Dividend Assets Capital LLC purchased a new stake in IQVIA in the first quarter worth approximately $27,000. Johnson Financial Group Inc. purchased a new stake in IQVIA in the fourth quarter worth approximately $34,000. Quent Capital LLC boosted its stake in IQVIA by 271.8% in the first quarter. Quent Capital LLC now owns 145 shares of the medical research company’s stock worth $34,000 after buying an additional 106 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its stake in IQVIA by 243.2% in the first quarter. EverSource Wealth Advisors LLC now owns 151 shares of the medical research company’s stock worth $35,000 after buying an additional 107 shares in the last quarter. Hedge funds and other institutional investors own 86.77% of the company’s stock.
IQVIA Price Performance
IQV opened at $190.62 on Friday. The stock has a fifty day simple moving average of $223.64 and a two-hundred day simple moving average of $220.07. The company has a current ratio of 0.96, a quick ratio of 0.96 and a debt-to-equity ratio of 2.36. The company has a market cap of $35.55 billion, a price-to-earnings ratio of 31.82, a price-to-earnings-growth ratio of 1.79 and a beta of 1.34. IQVIA Holdings Inc. has a 12-month low of $190.46 and a 12-month high of $285.61.
Analyst Ratings Changes
A number of research firms have recently weighed in on IQV. SVB Leerink began coverage on IQVIA in a research note on Friday, July 15th. They set an “outperform” rating and a $256.00 price objective for the company. Barclays dropped their price objective on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research note on Monday, September 12th. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday. Evercore ISI increased their price objective on IQVIA from $265.00 to $275.00 in a research note on Friday, July 22nd. Finally, Robert W. Baird increased their price objective on IQVIA from $260.00 to $265.00 in a research note on Friday, July 22nd. Two analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $275.00.
IQVIA Company Profile
IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
- Get a free copy of the StockNews.com research report on IQVIA (IQV)
- What Steelcase’s Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.